ClinicalTrials.gg
RecruitingNCT05999643Updated Aug 21, 2023

Characterizing Spondyloarthritis With 68Ga-FAPI PET/CT

An interventional study of Drug: 68Ga-FAPI in Spondyloarthritis, Axial Spondyloarthritis and Ankylosing Spondylitis, sponsored by The First Affiliated Hospital of Xiamen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-21.

Primary conditionSpondylitis, AnkylosingRegistry: SpondylarthritisReclassifiedWhy we changed it
Registry
Spondylarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spondylitis, Ankylosing
Why
  1. The study's listed conditions name Spondylitis, Ankylosing, a narrower term within Spondylarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The First Affiliated Hospital of Xiamen University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
52nd of 62
50 · median 150
Started
2023
with 6 others
No phase
8 of 77
2 open now
Primary completion
2024-08
later than 0 of 22 live
Registered
51st of 77
by date

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 52nd largest by planned enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 8 with no phase, reaches primary completion later than 0 of the 22 other live ones, and was the 51st registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis, inflammation evaluation and prognosis prediction in spondyloarthritis.

Read the detailed description

Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease characterized by inflammatory back pain, enthesitis, dactylitis, and the formation of syndesmophytes, all of which significantly affect a patient's healthy functioning and general quality of life. Prevalence of underlying malignancy is high in patients with SpA. Radiographic sacroiliitis became a crucial finding in the diagnosis and classification of patients.

68Ga-FAPI has been developed as tracers specific for fibroblast-activation protein (FAP), which is overexpressed in activated fibroblasts in various type of cancers and autoimmune diseases, such as rheumatoid arthritis, IgG4-related diseases and interstitial lung diseases.

Recently the investigators have published articles of the application of 68Ga-FAPI in IgG4-related disease and rheumatoid arthritis, which showed it was more sensitive than FDG in detecting a certain type of inflammation. Increased 68Ga-FAPI Uptake in ankylosing spondylitis in a patient with rectal cancer has also been reported in a case report, indicating the potential utility of FAP-targeted PET/CT imaging for diagnosis and disease assessment in spondyloarthritis.

Thus, this prospective study is going to investigate utility of 68Ga-FAPI PET/CT in diagnosis of spondyloarthritis as well as inflammation assessment in joints including the sacroiliac (SI) joints, spine and peripheral joints. Also, this study aims to investigate potential utility of 68Ga-FAPI PET/CT in predicting treatment response and disease prognosis such as formation of syndesmophytes and erosive changes.

03

Conditions studied

  • Spondyloarthritis
  • Axial Spondyloarthritis
  • Ankylosing Spondylitis

Browse trials for

Keywords

  • Spondyloarthritis
  • Axial Spondyloarthritis
  • Ankylosing Spondylitis
  • 68Ga-FAPI
04

In context

Spondylitis, Ankylosing Reclassified

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

This study's planned enrollment of 50 is below the median of 87 across 304 interventional studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

The First Affiliated Hospital of Xiamen University is the lead sponsor of 120 studies on the registry; 81 are open to participants now.

Compared within Spondylitis, Ankylosing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spondylarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of SpA according to the ASAS (Assessment of Spondyloarthritis International Society) classification criteria for SpA.
  2. Adult men or women 18 and ≤ 65 years of age at the time of signing the (ICF).
  3. participants who were able to provide informed consent (signed by participant or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy;
  2. Breastfeeding;
  3. known allergy against FAPI;
  4. any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Inject 68Ga-FAPI and then perform PET/CT scan.

    Inject 68Ga-FAPI and then perform PET/CT scan

    Diagnostic Test: Drug: 68Ga-FAPI

Interventions

  • Diagnostic testDrug: 68Ga-FAPI

    Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image SpA lesions in SI joints, spine, musculoskeletal and the extra-articular involvement by PET/CT.

    Also known as: 68Ga-fibroblast activating protein inhibitors

07

What researchers measure

Primary outcomes

  1. To define the distribution pattern of 68Ga-FAPI in SpA patients.

    To quantify 68Ga-FAPI tracer biodistribution in characteristic inflammatory tissue including SI joints, spine, and the peripheral joints versus conventional x ray examination or magnetic resonance imaging (MRI) techniques in adult active SpA. 68Ga-FAPI PET tracer biodistribution will be assessed by semi-quantitative analysis (unit/metrics = standardized uptake values (SUV)).

    Time frame: 60 minutes following injection

Secondary outcomes

  1. Correlation between uptake of 68GA-FAPI and other parameters associated with disease activity.

    Correlation between uptake of 68GA-FAPI and parameters associated with disease activity including Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath ankylosing spondylitis disease activity index (BSADAI), Bath ankylosing spondylitis functional index (BASFI),and Maastricht Ankylosing Spondylitis Enthesitis Score(MASES). The Standardized uptake value (SUV) of 68Ga-FAPI was calculated and analyzing the correlation between pathological results and parameters associated with disease activity.

    Time frame: 30 days

  2. Correlation between uptake of 68GA-FAPI change and disease activity change

    Correlation between change in standardized uptake value (SUV) of 68Ga-FAPI at inflammatory site with change in Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath ankylosing spondylitis disease activity index (BSADAI), Bath ankylosing spondylitis functional index (BASFI),and Maastricht Ankylosing Spondylitis Enthesitis Score(MASES) at different disease stage.

    Time frame: Up to 2 years

  3. Correlation between uptake of 68GA-FAPI and therapy response

    Percentage of participants achieving ankylosing spondylitis disease activity score inactive disease \[ASDAS ID (\<1.3)\] after 1 year standardized treatment in participants with high standardized uptake value (SUV) of 68Ga-FAPI and low standardized uptake value (SUV) of 68Ga-FAPI at baseline.

    Time frame: Up to 2 years

08

Study locations

1 of 1 sites recruiting
  • The first affiliated hospital of Xiamen University
    Xiamen, Fujian 361000, China
    Recruiting
    • Qiuwan Wu, PhD · Contact86 0592-2137507
    • Yuan Liu, MD · Principal investigator
    • Haojun Chen, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2024, 13 months after the start.

Of 62 non-industry interventional studies with no phase under Spondylitis, Ankylosing, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 13 months is close to that.

Counting every sponsor, half of 65 studies reached it within 12 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2023
First posted
Aug 21, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2025
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05999643
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jul 1, 2023
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Aug 21, 2023

Study contacts

Yuan Liu, MD
Contact
iuyuan@xmu.edu.cn
86 0592-2137749
Haojun Chen, PhD
Contact
leochen0821@foxmail.com
86 0592-2137166
Guixiu Shi, PhD
study director · The First Affiliated Hospital of Xiamen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion